Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 6/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.47 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8385934 | 1.00 | TYMP (0.55) | TYMPADORA1P2RY12ADORA2AADORA2B | |
| SCHEMBL8385935 | 1.00 | TYMP (0.55) | TYMPADORA1P2RY12ADORA2AADORA2B | |
| SCHEMBL29814199 | 1.00 | TYMP (0.55) | TYMPADORA1P2RY12ADORA2AADORA2B | |
| SCHEMBL20482910 | 1.00 | TYMP (0.55) | TYMPADORA1P2RY12ADORA2AADORA2B | |
| SCHEMBL31419333 | 0.95 | TYMP (0.55) | TYMPADORA1P2RY12ADORA2AADORA2B | |
| SCHEMBL6396836 | 0.95 | TYMP (0.55) | TYMPADORA1P2RY12ADORA2AADORA2B | |
| SCHEMBL21305068 | 0.95 | TYMP (0.55) | TYMPADORA1P2RY12ADORA2AADORA2B | |
| SCHEMBL19493438 | 0.95 | TYMP (0.55) | TYMPADORA1P2RY12ADORA2AADORA2B | |
| SCHEMBL8381924 | 0.95 | TYMP (0.55) | TYMPADORA1P2RY12ADORA2AADORA2B | |
| SCHEMBL18797894 | 0.95 | TYMP (0.55) | TYMPADORA1P2RY12ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10633411-B2 | Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-04-28 | — | — | US | disclosed |
| US-10508129-B2 | Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10508129-B2 | Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway | CGAS, GMPS, STING1 | TYMP 221/4885ADORA1 443/4885P2RY12 304/4885 |
| US-10633411-B2 | Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway | CGAS, GMPS, STING1 | TYMP 221/4885ADORA1 443/4885P2RY12 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.